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Human mesenchymal stem cells (hMSCs), also called mesenchymal stromal cells, have been of great interest in
regenerative medicine applications because of not only their differentiation potential but also their ability to secrete
bioactive factors that can modulate the immune system and promote tissue repair. This potential has initiated
many early-phase clinical studies for the treatment of various diseases, disorders, and injuries by using either hMSCs
themselves or their secreted products. Currently, hMSCs for clinical use are generated through conventional static
adherent cultures in the presence of fetal bovine serum or human-sourced supplements. However, these methods
suffer from variable culture conditions (i.e., ill-defined medium components and heterogeneous culture
environment) and thus are not ideal procedures to meet the expected future demand of quality-assured hMSCs for
human therapeutic use. Optimizing a bioprocess to generate hMSCs or their secreted products (or both) promises
to improve the efficacy as well as safety of this stem cell therapy. In this review, current media and methods for
hMSC culture are outlined and bioprocess development strategies discussed.Introduction
Human mesenchymal stem cells (hMSCs) were first iso-
lated from bone marrow but have since been found in
other tissues in the body, such as adipose tissue, umbil-
ical cord blood, the Wharton jelly of the umbilical cord,
synovium, lung, pancreas, and muscle [1–3]. Whereas
these other hMSC sources have emerged in the last few
years and are being studied, bone marrow-derived
hMSCs (BM-hMSCs) have been rigorously studied over
many years and are used in the majority of hMSC
clinical studies and trials. The clonogenic BM-hMSC
fraction ranges from 10 to 100 CFU-F (colony-forming
unit—fibroblast) per 106 marrow mononuclear cells
(MNCs) and is typically isolated and expanded in classic
serum-based media on tissue culture plastic. BM-hMSCs
are characterized by (a) their adherence to plastic; (b)
multipotency (i.e., adipogenic, osteogenic, and chondro-
genic differentiation); (c) positive expression of surface
antigens CD73, CD90, and CD105; and (d) lack of
CD34, CD45, CD14 or CD11b, CD19 or CD79α, and* Correspondence: behie@ucalgary.ca
1Pharmaceutical Production Research Facility, Schulich School of Engineering,
University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada
Full list of author information is available at the end of the article
© 2015 Panchalingam et al. Open Access Thi
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeHLA-DR expression [4]. In addition to their multipo-
tency, hMSCs have been shown to have the ability to se-
crete bioactive factors which can modulate the immune
system (e.g., indoleamine 2,3-dioxygenase and prosta-
glandin E2) and promote tissue repair (e.g., glial cell line-
derived neurotrophic factor and vascular endothelial
growth factor, or VEGF) [5]. In fact, it is widely accepted
that the majority of hMSC-mediated therapeutic benefits
are due to their secretion of bioactive molecules as it
has been shown that these factors have various therapeutic
effects both in vitro and in vivo (i.e., anti-inflammatory,
anti-fibrotic, anti-apoptotic, anti-angiogenic, or immuno-
modulatory) as well as repair/regenerative actions. To
generate hMSCs for clinical studies, it is necessary to first
expand these cells for several passages in vitro, after which
adequate potency testing should be performed before cell
infusion.
Any bioprocess used to produce therapeutic cells
needs to be carefully designed, as this process is dis-
tinctly different from the well-known processes used to
produce biopharmaceuticals. The first of these differ-
ences is that each batch or lot of therapeutic cells gener-
ated to treat one patient would be much smaller thans article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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tion. Although hMSCs can be expanded for more than
40 population doublings (PDs) in culture, it has been
suggested that cells of fewer than 20 PDs, particularly
BM-hMSCs, be used for clinical applications with regard
to safety and efficacy to avoid possible cell transform-
ation [6, 7].
The second difference compared with therapeutic pro-
tein production is that hMSCs are the therapeutic prod-
uct themselves. Thus, it is critical to produce functional
hMSCs that retain their therapeutic properties. In this
regard, it is important to develop a bioprocess for the
expansion of hMSCs in a well-defined environment,
where the nutritional, physiochemical, and mechanical
requirements are met, controlled, and maintained (i.e.,
in bioreactors) for the culture period in order to gener-
ate consistent quantities of cells with the same desired
properties. If variability is present between batches, this
could undermine the therapeutic properties of the
hMSCs. Hence, it is important to produce hMSCs for
therapeutic applications in a well-defined manner (i.e.,
defined medium formulation) under good process con-
trol (i.e., online computer control in bioreactors) which
can be operated in a closed system according to Good
Manufacturing Practice (GMP).
Human mesenchymal stem cell culture
Culture media
Conventional medium used for isolating and expanding
hMSCs is typically a defined basal medium—i.e., Dulbec-
co’s modified Eagle’s medium (DMEM)—supplemented
with fetal bovine serum (FBS): 10–20 % (vol/vol). How-
ever, concerns exist with the use of FBS for clinical use:
namely (a) the variability of FBS from batch to batch, (b)
its ill-defined nature, and (c) the possibility that FBS
contains harmful contaminants such as prions, viral, and
zoonotic agents. Moreover, when hMSCs are cultured in
a medium containing animal proteins, a substantial
amount of these proteins is retained in the cytoplasm of
hMSCs, which may elicit an immunologic reaction when
the cells are transplanted in vivo [8]. It is for this reason
that, even though FBS is still widely used in hMSC re-
search, it has been suggested (by our group and others)
that the development of a defined serum-free medium is
needed for the expansion of quality-assured clinically ac-
ceptable hMSCs [9–11].
Humanized media
To find a suitable replacement for FBS, human blood-
derived materials such as human serum and platelet deriv-
atives have been investigated as an alternative medium
supplement (reviewed in [10, 12]). Although human
autologous serum has been reported to support hMSC
expansion, it would be difficult to procure sufficientquantities of this serum to generate clinically relevant
numbers of hMSCs [13–15]. Allogeneic human AB serum
would circumvent this issue as several donor serums
could be pooled to eliminate donor-specific differences
and produced in a large-scale manner. Moreover, some
groups have reported that it performs as well as FBS
[16–18]. It has also been reported by many groups that
human platelet lysate (hPL) or platelet-rich plasma have
considerable growth-promoting properties for hMSCs
while maintaining their differentiation potential and im-
munomodulatory properties [19–22]. However, one
study reported that although hPL supported the expan-
sion of hMSCs, it also impaired their immunomodula-
tory capacity [23]. Moreover, two other studies reported
that a reduction in the osteogenic or adipogenic differ-
entiation potential was seen in hPL-expanded hMSCs
[24, 25]. Although these alternatives may be safer than
using FBS and are currently being exploited for some
clinical trials, the use of human-sourced supplements is
still a matter of substantial debate, prompting concern
in that there is still a risk that these supplements might
be contaminated with human pathogens not detected by
routine screening of blood donors. Moreover, these
crude blood derivatives are poorly defined and can suf-
fer from batch-to-batch variation (as reported for hPL
in [26]), and thus their ability to maintain hMSC growth
and therapeutic potentials could be widely variable. As
it can be difficult to obtain reproducible and consistent
cell quantities and qualities using these human sources,
it can be a hindrance in the development of quality-
assured hMSCs for large clinical studies. Therefore, ef-
fort should be made to standardize the production of
these materials, limit the donor-to-donor variability
(i.e., through pooling), and establish methods for patho-
gen inactivation [27, 28].
Defined serum-free media
There has been much progress in the last few years to
develop serum-free media for the isolation and expan-
sion of primary hMSCs (reviewed in [10, 29]). Although
numerous commercial formulations have been released,
our group reported in detail the first defined serum-free
medium formulation (i.e., PPRF-msc6) which supported
the rapid isolation and expansion of hMSCs from BM
MNCs and their subsequent passages while maintaining
their immunophenotype and multipotency [9, 30].
To the best of our knowledge, only two commercial
serum-free media have been shown to support the isola-
tion and expansion of primary hMSCs. Miwa et al. re-
ported that they were able to isolate and expand hMSCs
from BM MNCs in Mesencult-XF (Stemcell Technolo-
gies, Vancouver, BC, Canada) and in comparison with
serum-supplemented culture observed higher cumulative
PDs of 22–23 PDs in Mesencult-XF and 13–14 PDs in
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et al. reported that they were able to isolate and expand
hMSCs from BM MNCs in Becton Dickinson (Franklin
Lakes, NJ, USA) Mosaic hMSC Serum-Free medium
(BD-SF) and achieve cell yields comparable to that
achieved for cells isolated and expanded with
Mesencult-XF [10]. However, the formulations of these
commercial media are not disclosed, and thus it may
restrict their wide utility in hMSC research and clinical
studies where the formulations cannot be exploited or
modified.
Culture mode
Adherent and spheroid culture
hMSCs are typically isolated and characterized by their
adherence to plastic. However, the adherent culture of
hMSCs may alter their phenotype and therapeutic proper-
ties as it represents an environment which is a different
from their niche in vivo [32]. In fact, many observations
have suggested that pre-conditioning hMSCs with either
biological factors or the culture condition can enhance the
therapeutic properties of hMSCs [33–36]. One method is
the culture of hMSCs as spheroids (reviewed in [32]). In
fact, Bartosh et al. found that the aggregation of hMSCs
enhanced their anti-inflammatory properties, namely the
increased expression of TSG-6 and stanniocalcin-1 [37].
Also, spheroid culture expressed high levels of three anti-
cancer proteins: interleukin-24, tumor necrosis factor-
alpha (TNF-α)-related apoptosis-inducing ligand, and
CD82 [37]. Zimmermann and McDevitt also observed
that the formation of hMSC aggregates can enhance the
anti-inflammatory properties of the cells and that if the
cells are treated with TNF-α and interferon-gamma they
can inhibit the secretion of TNF-α by macrophages [38].
The benefit of spheroid culture has also been observed in
pre-clinical studies where transplantation of hMSCs from
adipose tissue into porcine models improved cell reten-
tion, survival, and integration [39, 40]. However, for this
culture method to be applied in the clinic on a large scale,
robust data on the growth kinetics and phenotype of the
cells will need to be gathered. As Zimmermann and
McDevitt noted, the immunomodulatory factor secre-
tion was highly dependent on the composition of the
cell culture medium [38]. And it may be necessary to
re-develop a medium more suitable to the expansion of
hMSCs as spheroids (rather than as adherent cells), as
was done by Alimperti et al. [41].
Normoxic and hypoxic culture
The expansion of hMSCs in vitro has often been done at
atmospheric oxygen levels of 21 %. It has been reported
that exposure of hMSCs to these levels can induce DNA
damage, contributing to cellular senescence and decreased
therapeutic efficacy [42]. When culturing hMSCs atphysiological oxygen levels (i.e., 1–5 %), an increase in cell
growth and an increase in their adipogenic and osteogenic
differentiation have been observed [43]. Additionally,
hMSCs expanded at these low oxygen conditions have
limited oxidative stress, DNA damage, telomere shorten-
ing, and chromosomal abnormalities [42]. Also, the expos-
ure of hMSCs to low physiological oxygen levels can
pre-condition them before transplantation and increase
their therapeutic ability [44–47]. To mimic the ischemic
microenvironment, serum-expanded hMSCs were placed
in a serum-deprived medium under hypoxia and were
found to secrete increased levels of pro-angiogenic factors
that included VEGF-A, angiopoietins, insulin-like growth
factor 1, and hepatocyte growth factor (HGF) [48].
Additionally, using an in vivo modified chick chorioallan-
toic membrane angiogenesis assay, the hypoxic-serum-
deprived hMSCs displayed significantly higher angiogenic
potential compared with typical culture-expanded hMSCs.
Recently, Chang et al. showed that hypoxic precondition-
ing of BM-hMSCs and transplantation of this conditioned
medium (CM) into rats with experimental traumatic brain
injury (TBI) resulted in these rats performing significantly
better in both motor and cognitive function tests as well
as showing increased neurogenesis and decreased brain
damage compared with TBI rats transplanted with CM
collected from normoxic-expanded BM-MSCs [44]. More-
over, hypoxic conditions were able to stimulate the BM-
hMSCs to secrete higher levels of VEGF and HGF. There-
fore, given these observations, it may be necessary to con-
sider expanding hMSCs in hypoxic conditions before
transplanting the cells in vivo, in order to enhance their
survival and therapeutic potential.
Large-scale expansion
There are many types of bioreactors used for the expan-
sion of hMSCs (reviewed in [49–52]). The most widely
used bioreactors in the laboratory are tissue culture
flasks, which provide a surface for hMSCs to adhere to
and which are available with different surface areas: 25,
75, 150, and 225 cm2. These are cost-efficient and easy-
to-operate and provide good gas exchange with the ex-
ternal environment through a filter cap or cracked plug
cap and ample headspace. However, for the generation
of a large number of hMSCs in clinical applications, a
large number of tissue culture flasks would be required.
Dealing with a large number of these flasks not only is
very labor intensive but also tends to result in flask-to-
flask variability. Additionally, handling multiple vessels
increases the chance of contamination with external
agents (i.e., bacterial). In this regard, the use of tissue
culture flasks would not be appropriate for the expan-
sion of a clinically relevant number of hMSCs. For the
scalable expansion of hMSCs, there are many available
bioreactors, including multi-layered cell factories, roller
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bioreactors, to name a few. Each bioreactor has its own
specific features (and benefits), and thus it is important
to compare the different bioreactors and select the best
one for the large-scale expansion production of quality-
assured hMSCs. In this section, we will briefly review
two main bioreactors, multi-layered cell factories and
stirred suspension bioreactors (using microcarriers),
which are currently used for the large-scale production
of hMSCs.
Multi-layered vessels
The multi-layered cell factory represents the simplest
system for scaling up from monolayer culture as it has a
geometry and substrate similar to those of a T-flask. It
offers a large surface area for cell growth by layering
stacks of ‘flask-units’ on top of each other. Typically,
each cell factory ‘unit’ consists of 1 to 40 stacks that are
connected together (i.e., Nunc Cell Factory, Thermo
Fisher Scientific, Waltham, MA, USA; Corning Cell-
STACK; Corning, Corning, NY, USA), where extra layers
can be added. And recent innovations, such as the Corn-
ing Hyperstack, have tripled the surface area per volume
of traditional multilayer vessels and offer vessels con-
taining 120 layers. This method of cell expansion has been
used by many investigators to expand hMSCs [53–56].
In particular, Bartmann et al. [53] reported that the
growth of hMSCs in cell factories was similar to that of
T-225 flasks, and in order to obtain a clinical dose of
hMSCs (>200 × 106 cells), four to 10 four-layered cell
factors were used. Owing to its easy implementation
and scale-up achieved by simply increasing the size and
number of layers, it has been used by companies in clin-
ical trials as their main expansion technology [57].
However, this process is difficult to monitor and control
throughout the culture period. Moreover, difficulties in
achieving a uniform distribution of cells and in harvest-
ing could result in increased culture heterogeneity and
suboptimal yield of cells [58]. Thus, this system in its
current form may not be ideal if higher cell doses are
required for an application. Pall Life Sciences (Port
Washington, NY, USA) has introduced a single-use bio-
reactor technology, Integrity Xpansion, that is a closed
system containing up to 122,400 cm2 of growth area,
and integrated temperature, dissolved oxygen, and pH
control. Although this system has been shown to support
expansion of MSCs, the potency of these cells has yet to
be reported [59].
Stirred suspension bioreactors
Stirred suspension bioreactors are relatively simple ves-
sels that have a centrally located impeller, which agitates
the contents of the vessel and provides relatively uni-
form conditions throughout the medium. The impellerspeed is controlled by either a magnetic field generated
by a stirrer placed under it or a top-driven motor. Cur-
rently, there are a number of stirred suspension bioreac-
tors available at different volumes, such as the DASGIP
Parallel Bioreactor system and Celligen (Eppendorf,
Hauppauge, NY, USA), PADReactor (Pall Life Sciences),
and MiniBio (Applikon Biotechnology, Delft, The
Netherlands), to name a few. By means of stirred sus-
pension bioreactors, a large number of cells can be ex-
panded in one vessel, thereby avoiding vessel-to-vessel
variability (i.e., as is the case with multiple T-flasks) and
minimizing costs related to labor and consumables.
Additionally, these bioreactors can be operated in a
number of modes: batch (i.e., medium is not replaced),
fed-batch (i.e., intermittent medium replacement), or
perfusion (i.e., continuous medium replacement). Oper-
ating the bioreactors in a fed-batch or perfusion mode
ensures that key nutrients are replenished and metabolic
waste products (i.e., lactate and ammonium) are kept at
safe levels. Furthermore, these bioreactors can be
equipped with computer-controlled online-monitoring
instruments that ensure tight control of process vari-
ables such as pH, temperature, and dissolved oxygen
concentration. Moreover, single-use, closed bioreactors
(e.g., Cultibag STR; Sartorius AG, Göttingen, Germany)
are available, enabling GMP production of cells in a class
C or D room and not in a class A cabinet or B room
[60]. Based on these advantages, stirred suspension bio-
reactors have been used for the culture of stem cells,
which grow as tissue aggregates or adherent cells using
microcarriers.
Used in suspension culture, microcarriers are small
beads that have a diameter of between 100 and 300 mi-
crons and provide a large surface-to-volume area for
anchorage-dependent cells to attach and grow. They can
be easily maintained in suspension in liquid medium
and provide a high surface area-to-volume ratio (i.e.,
microporous microcarriers can provide a ratio of
30 cm2/cm3 medium at a bead loading of 10 g/l (Cyto-
dex 3 microcarriers; GE Healthcare, Little Chalfont,
UK), whereas T-flasks have a smaller ratio of 3 cm2/cm3
medium), which allows much higher cell yields to be
achieved in suspension culture. These microcarriers are
typically made of various materials, including collagen,
dextran, and glass, which have varying surface properties
that affect cell growth kinetics and phenotype.
A number of investigators have shown that MSCs de-
rived from multiple sources, such as the bone marrow,
placenta, and ear, could be expanded on microcarriers
[61–63]. When this technology was first developed, the
cell yield was low and variable compared with those of
expanding cells in static culture flasks. Therefore, further
efforts were required to optimize this culture system be-
fore it could be considered comparable to that of static
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three main variables: (1) microcarrier selection, (2)
microcarrier-loading/cell-seeding density, and (3) medium
composition. For a further review, see [64]. Additionally,
we will discuss the design considerations for scaling up
suspension bioreactors.
Microcarrier selection
The selection of an appropriate microcarrier is import-
ant as it can impact the growth kinetics as well as the
phenotype of the expanded cells. Moreover, microcarrier
screening should be done in the same culture system as
will be used for their large-scale implementation, in
order to incorporate the influence of the culture envir-
onment on the performance of the microcarriers. Micro-
porous microcarriers have been investigated for many
years and can have different surface properties and coat-
ings, which influence cell attachment and subsequent
cell expansion. Also, the source and isolation method of
hMSCs can affect their subsequent expansion on micro-
carriers, and thus it is important to identify one that
works specifically for a given process. However, in gen-
eral, it has been shown for hMSCs that cell-adhesive
coatings (i.e., collagen) can promote attachment and
proliferation of fastidious cells [65].
It has also been reported that macroporous and bio-
degradable microcarriers have been evaluated for the
growth of hMSCs [66–68]. These microcarriers allow
cells to grow internally and therefore are protected from
the hydrodynamic shear present in the stirred bioreac-
tors. Additionally, by using biodegradable microcarriers,
hMSC recovery may be higher or the hMSCs and micro-
carriers could be transplanted in vivo without their sep-
aration. This may be beneficial if the therapeutic effect is
intended to be localized at the site of administration.
However, as in the development of serum-free media, it is
also important to evaluate the use of animal component-
free microcarriers. Three groups thus far have published
results on the use of xeno-free microcarriers, which
have shown the ability to support the growth of
hMSCs [69–71].
Microcarrier-loading and cell-seeding density
Microcarrier density and cell-to-bead (microcarrier) ra-
tio are well known variables that affect not only the ini-
tial cell attachment efficiency but also the level of
culture compactness. Cell attachment to microcarriers
follows a Poisson distribution [72], in which for a cell-
to-bead inoculation ratio of 1, 2, 3, and 4 cells per bead,
the theoretical probabilities of unoccupied microcarriers
are 0.365, 0.135, 0.05, and 0.018, respectively. Addition-
ally, these probabilities are likely to be increased under
nonoptimal inoculation conditions (e.g., inhibitory
medium components, suboptimal microcarrier type,cellular damage, or adverse pH). Therefore, it is important
to inoculate cells at a sufficiently high cell-to-bead ratio in
order to achieve a good distribution in which each bead is
occupied by at least one viable cell. For hMSC culture,
cell-to-bead ratios of between 3 and 5 cells per bead and
microcarrier densities of between 1 and 4 g (dry weight)
per liter have been used. Based on these typical cell inocu-
lation and microcarrier densities (i.e., 2 g/l), most re-
searchers have achieved a final hMSC concentration in
the range of 1–4 × 105 cells/ml [66, 70, 71]. In contrast,
other mammalian cells used in industrial microcarrier cul-
ture achieve a final cell density of around 2 × 106 cells/ml
[73]. The large difference in final cell culture concentra-
tions may be attributed to suboptimal culture conditions,
including microcarrier-loading and cell-seeding densities.
Therefore, to increase the final hMSC cell concentration,
higher microcarrier densities may be used. However, with
higher-density cultures, it may be necessary to increase
medium oxygenation (i.e., sparging) and establish more
frequent medium feedings to supply adequate oxygen and
nutrients.
Medium composition
In conventional serum-based media, hMSCs in micro-
carrier culture exhibit a prolonged lag phase and low
growth rate [66, 72, 74]. Minimizing the lag phase and
maximizing the rate and length of the exponential
growth phase are requirements in designing a good bio-
process. We have recently published results showing
good expansion of hMSCs on Cytodex 3 microcarriers,
in a serum-free medium formulation (PPRF-msc6), in
125-ml suspension bioreactors [64]. Compared with
hMSCs expanded in 10 % FBS DMEM, hMSCs in PPRF-
msc6 had a significantly shorter lag phase and reached a
higher cell density at an earlier time point (4.38 ± 0.23 ×
105 cells/ml on day 6). Eibes et al. had also reported that
using a low-serum medium significantly enhanced the
expansion of hMSCs compared with 10 % FBS DMEM
[66]. This has also been observed by researchers using
other serum-free media to expand hMSCs in microcar-
rier culture [70, 71]. However, we also observed that dif-
ferent hMSC donors (BM1, BM2, and BM3) had variable
growth kinetics in our 125-ml suspension bioreactors
(Fig. 1) but that in concurrent static T-flasks, the growth
kinetics of the cells were comparable. This may be due
to optimizing our microcarrier bioprocess by using one
hMSC donor (BM3) while our other donors might re-
quire different culture parameters (e.g., microcarrier type
and cell-seeding density). This would explain why the
maximum cell density achieved is higher for BM3 cells
compared with the other two hMSC cell lines (Fig. 1).
Therefore, although microcarrier technology is an at-
tractive option for the production of clinically relevant
hMSCs, a number of variables will be need to be
Fig. 1 Expansion of bone marrow-derived human mesenchymal stem cells (BM-hMSCs) on Cytodex 3 microcarriers in serum-free PPRF-msc6
medium in 125-ml stirred suspension bioreactors [84]. hMSCs isolated in PPRF-msc6 were thawed and expanded for two passages in PPRF-msc6
and then inoculated at 2.4 × 104 cells/ml in stirred suspension bioreactors containing 2.0 g/l of Cytodex 3 microcarriers. We observed variable cell
growth kinetics between different BM donors (BM1, BM2, and BM3). This indicates that although this bioreactor system was optimized for the
growth of one hMSC donor, inter-donor differences influence the growth kinetics of hMSCs in stirred suspension bioreactors. Error bars represent
the observed range, n = 2
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consistent, high-performance bioprocess.
Design considerations for scale-up of suspension
bioreactors
To scale-up bioreactor cultures, two key variables need
to be taken into account: (a) oxygen supply and (b)
hydrodynamic shear in the liquid medium. The specific
oxygen consumption rate of exponentially growing
mammalian cells has been reported to be between 1.7 ×
10−17 and 17.0 × 10−17 mol O2/cell∙s [73]. If cells use
oxygen faster than it is being supplied to a bioreactor,
then the dissolved oxygen level will decrease to a point
where the culture may not support cell growth. Gilbert-
son showed that with surface aeration, for the culture of
mouse neural stem cells, the mass transfer of oxygen
from the headspace to the bulk medium would support
the oxygen demands of cells at a density of 1 × 106 cells/
ml and would not be limiting up to 1.0 l of culture in a
cylindrical-shaped bioreactor [75]. Given current hMSC
growth kinetics, surface aeration would be adequate for
scaling-up hMSC suspension bioreactor bioprocesses to
1.0 l. Further studies are needed to address the oxygen
limitation issue at higher scales.
Hydrodynamic shear is another important characteris-
tic to consider. In stirred suspension bioreactors, the agi-
tation rate of the impeller governs the hydrodynamic
shear within the vessel, and as the agitation increases
the hydrodynamic shear rate increases. If the agitationrate is too low, the culture may not be well mixed, caus-
ing problems such as a significant aggregation of cells
and microcarriers and nonhomogeneous culture envir-
onment. The uncontrolled aggregation may cause lim-
ited transfer of oxygen and nutrients to cells inside large
aggregates. However, if the agitation rate is too high, this
can be detrimental if it causes excessive cell damage. To
estimate the hydrodynamic shear, the Kolmogorov’s the-
ory of turbulent eddies [76] and the Nagata correlation
[77] have typically been used in order to maintain the
same maximum shear rate. However, this calculation
does not take into account the flow regime present in
the vessel and these values differ between different bio-
reactor configurations that may impact the growth of
the cells. Consequently, it has also been suggested that
suspension experiments and computational fluid dynam-
ics studies combined with particle image velocimetry
measurements be used to determine optimal scale-up
operating parameters [78].
Cell-based (hMSC) or cell-free therapy (hMSC
secretome)?
As discussed, when therapeutically viable hMSCs are
generated, it is important to consider the effect that the
bioprocess has on the cell yield and cell properties.
Moreover, it is important to consider the downstream
process and, in particular, how these cells might be
transplanted into patients in hospitals. Currently, the
majority of hMSC clinical trials are administering
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cells are produced in one location, tested for sterility,
and then shipped to transplantation centers where they
may not be administered immediately. Therefore, it is
cost-effective to freeze the cells and thaw them only
once they are needed. However, this may be unwise as
all pre-clinical studies of hMSCs in disease models usu-
ally involve transfusion/transplantation of live MSCs
harvested during their log phase of growth.
Recently, it was shown that the therapeutic properties
of hMSCs are impaired by this freeze–thaw [80, 82].
Moreover, if the cells were thawed and cultured in vitro,
the hMSCs reverted back to their noncryopreserved
phenotype and recovered their therapeutic properties
[79, 80]. However, this may not be possible in a hospital
setting where specialized equipment is required and spe-
cifically trained personnel who can generate the hMSCs
are required for each patient disease intervention. In this
regard, the production of the hMSC secretome (i.e., the
CM: the medium containing the hMSC-secreted factors
but is cell-free) may present a better avenue for the clin-
ical application of hMSCs as it has been shown that this
medium can be injected in vivo for clinical benefit [34,
44, 48]. Additionally, it has been shown that by altering
the culture environment, the therapeutic properties of
hMSCs and their secreted products can be modulated
[33, 34, 44, 48].
We recently observed that we can enhance the neuro-
trophic properties of hMSCs by using PPRF-msc6
medium and our computer-controlled stirred suspensionFig. 2 Differentiation of human telencephalon-derived neural stem/prog
marrow-derived human mesenchymal stem cells (BM-hMSCs) expanded
(T-flasks) or (b )500-ml computer-controlled suspension bioreactors in PPRF-m
(blue). Conditioned medium collected from hMSCs expanded in PPRF-msc6/b
Additionally, hNPC survival was higher in the PPRF-msc6/bioreactor-expanded
static-expanded hMSC conditioned medium had a lower survival and differen
collected from our PPRF-msc6/bioreactor conditions contained factors that pr
the FBS/static conditioned medium was less effective in causing hMSCs to sebioreactors compared with conventional culture in static
culture flasks and 10 % FBS DMEM (Fig. 2). Specifically,
using the Kolmogorov’s theory of turbulent eddies and
the Nagata correlation, we scaled-up our hMSC cultures
from 125-ml suspension bioreactors to 500-ml computer-
controlled bioreactors on the basis of maintaining the
same maximum shear. hMSCs were inoculated at 4444
cells/cm2 either into static culture flasks containing 10 %
FBS DMEM or into computer-controlled stirred suspen-
sion bioreactors (DASGIP) containing 500 ml of PPRF-
msc6 medium with 2 g/l of Cytodex 3 microcarriers. The
cells were expanded for 72 hours, after which the cultures
were incubated with an equivalent amount of Neurobasal-
A medium (Life Technologies, Carlsbad, CA, USA) for
24 hours at the same culture process parameters. This
medium (herein called the CM) was collected after
24 hours. When the CM was incubated with human
neural precursor cells (hNPCs) (containing both stem and
progenitor cells; see discussion in [83]) for 7 days, the
hNPC survival was significantly higher in the PPRF-msc6/
bioreactor CM compared with the FBS/static-expanded
CM. Additionally, differentiation of hNPCs into MAP2+
neurons was significantly higher for hNPCs incubated
with the PPRF-msc6/bioreactor CM compared with the
FBS/static-expanded CM. These data suggest that the use
of computer-controlled stirred suspension bioreactors
with PPRF-msc6 can enhance the neurotrophic potential
of hMSCs. Therefore, by altering the hMSC culture mode,
we can generate novel trophic cocktails (i.e., the CM) that
could be produced centrally at one (or multiple locations)enitor cells (hNPCs) in conditioned medium collected from bone
in either (a) static culture in fetal bovine serum (FBS)-based medium
sc6 medium [84]. Shown are cells expressing MAP2 (red) and TO-PRO-3
ioreactor resulted in a higher differentiation of hNPCs to MAP2+ neurons.
hMSC conditioned medium. In contrast, hNPCs incubated in the FBS/
tiation into MAP2+ neurons. This indicates that the conditioned medium
omoted the survival and differentiation of hNPCs into neurons. However,
crete these factors. Scale bars: 50 μm
Panchalingam et al. Stem Cell Research & Therapy  (2015) 6:225 Page 8 of 10in accordance with GMP methods and then concentrated,
frozen, and shipped in ready-to-use packages. This would
negate the issue of setting up specialized cell culture facil-
ities within the hospital and the hiring of cell culture tech-
nicians and the hassle of planning patient interventions to
coincide with optimal hMSC harvesting during the log
phase of growth and would allow standardization of
hMSC treatments.Conclusions
hMSCs are currently being evaluated as a stem cell
treatment for a number of diseases and have been
shown to be safe in clinical trials. They are able to elicit
their therapeutic benefits through the secretion of bio-
active molecules that modulate the in vivo environment
and promote tissue repair/regeneration. However,
current methods to generate hMSCs suffer from vari-
able culture conditions because of ill-defined medium,
heterogeneous culture environment, and limited growth
surface area per culture. Additionally, the in vitro cul-
ture environment has been shown to modulate and in-
fluence the therapeutic ability of hMSCs and their
secretome. Thus, to meet the current and future de-
mand of clinically relevant numbers of hMSCs, it is ne-
cessary to develop a bioprocess that is well defined,
scalable, and under good process control which can be
operated in accordance with GMP. To this end, much
research has gone into investigating and optimizing a
number of ‘variables’ in the hMSC culture environment.
This research includes (1) the development of serum-
free media, (2) modification of the traditional culture
environment, and (3) development of scalable and con-
trollable culture systems.Note: This article is part of a thematic series Mesenchymal
stem/stromal cells—an update. Other articles in this series can be
found at http://www.biomedcentral.com/series/mesenchymal.Abbreviations
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